Nplate® (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia

Nplate Reduced Rates of Bleeding by More Than 30 Percent in Children Affected by Blood Disorder THOUSAND OAKS, Calif., April 19, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that The Lancet published results from a Phase 3 randomized, double-blind, placebo-controlled study of Nplate® (romiplostim) in children with symptomatic immune thrombocytopenia (ITP). The study showed that 52 percent of Nplate patients achieved a durable platelet response, compared with 10 percent of placebo-treated patients (p=0.002, odds ratio 9.1, 95 percent CI: 1.9, 43.2). "Children with ITP are at risk for serious bleeding events due to low platelet counts, which can be very frightening for thes...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news